Immunome Inc.

Immunome Inc. is a U.S.-based biotechnology company developing targeted oncology therapies, with a pipeline spanning clinical and preclinical assets. Its lead focus is varegacestat for desmoid tumors, alongside antibody-drug conjugate and radioligand programs aimed at cancer indications with high unmet need.

−3 193,3 %

−3 060,0 %

−23,2 %

14.69

14.69

— Immunome Inc.
%
Lead clinical oncology asset0% Varegacestat is the company's most advanced program, targeting desmoid tumors with planned NDA submission.
Antibody-drug conjugates0% ADC programs include IM-1021 and multiple preclinical solid tumor candidates built on the company's target and payload platform.
Radioligand therapy0% IM-3050 is a FAP-targeted radioligand therapy intended for oncology use after IND clearance.
Collaboration revenue100% Historical revenue came from a collaboration and option agreement with AbbVie, which has now terminated.

Immunome does not yet sell approved products commercially; its current 'customers' are primarily regulators, clinical...

  • Desmoid tumor treatment centersprimary

    Specialized centers that would prescribe varegacestat if approved, because desmoid tumors are a niche oncology indication.

  • Cancer hospitals and academic centersprimary

    Sites participating in trials and, later, using ADC or radioligand therapies for hematologic and solid tumors.

  • Strategic partnerssecondary

    Pharma or biotech partners that may collaborate on ex-U.S. commercialization or development.

  • Payers and health systemssecondary

    Organizations that will influence reimbursement and access for any approved oncology products.

Immunome is headquartered in the United States and expects to commercialize varegacestat first through a U.S...

  • •United States is the core operating and planned launch market
  • •Europe is a potential retained-rights or partnered market
  • •Commercial buildout would focus on specialized oncology centers
  • •R&D and clinical execution are global in scope through trials
  • •No country-level revenue disclosure was provided

The company is prioritizing late-stage development and regulatory preparation for varegacestat while continuing to...

01
Regulatory submission and launch preparation for varegacestatshort-term

This is the nearest-term value driver and the first potential commercial product.

02
Advance IM-1021 and IM-3050 clinical developmentmedium-term

These programs diversify the pipeline beyond the lead asset and validate the platform.

03
Broaden the ADC platform with preclinical assetsmedium-term

A wider pipeline increases the chance of future clinical and partnering success.

Immunome remains a development-stage biopharma company with no approved product revenue, so execution risk is...

high

Clinical development failure or delay

The pipeline is still in development, and setbacks in Phase 1/3 trials could postpone or eliminate future revenue.

Scope
Varegacestat, IM-1021, IM-3050 and preclinical ADCs
Materiality
high
high

Regulatory approval risk

The company has not yet obtained NDA/BLA approval, so commercialization depends on FDA and other regulators.

Scope
Lead asset varegacestat and future pipeline assets
Materiality
high
high

Financing and cash burn

R&D and launch preparation require substantial capital before product revenue begins.

Scope
Ongoing clinical development and commercial buildout
Materiality
high
medium

Competitive pressure in oncology

Larger pharma and biotech peers may reach market first or offer superior efficacy/safety.

Scope
Desmoid tumors, ROR1 ADCs, and broader oncology targets
Materiality
high
medium

Third-party manufacturing and supply dependence

Clinical and launch timelines depend on external manufacturing and diagnostic supply chains.

Scope
IM-3050 radiotracer supply and future commercial supply chain
Materiality
medium
Collaboration revenue recognition
No further collaboration revenue will be recognized from that contract
Research and development expense
Quarterly losses can change materially with program timing
Share-based compensation
Affects operating loss without immediate cash outflow
IPR&D and asset acquisition accounting
Can create large one-time charges and distort period comparability
Contingent milestone and royalty obligations
Potential future liabilities and cash outflows

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

Imunon, Inc.

IMNN · Pharmaceutical Preparations

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

IMAC Holdings, Inc.

BACK · Services-Specialty Outpatient Facilities, NEC

: 28.4.2026